Lipid Vesicles Loaded with an HIV-1 Fusion Inhibitor Peptide as a Potential Microbicide

The effective use of fusion inhibitor peptides against cervical and colorectal infections requires the development of sustained release formulations. In this work we comparatively study two different formulations based on polymeric nanoparticles and lipid vesicles to propose a suitable delivery nanosystem for releasing an HIV-1 fusion inhibitor peptide in vaginal mucosa. Polymeric nanoparticles of poly-d,l-lactic-co-glycolic acid (PLGA) and lipid large unilamellar vesicles loaded with the inhibitor peptide were prepared. Both formulations showed average sizes and polydispersity index values corresponding to monodisperse systems appropriate for vaginal permeation. High entrapment efficiency of the inhibitor peptide was achieved in lipid vesicles, which was probably due to the peptide's hydrophobic nature. In addition, both nanocarriers remained stable after two weeks stored at 4 °C. While PLGA nanoparticles (NPs) did not show any delay in peptide release, lipid vesicles demonstrated favorably prolonged release of the peptide. Lipid vesicles were shown to improve the retention of the peptide on ex vivo vaginal tissue in a concentration sufficient to exert its pharmacological effect. Thus, the small size of lipid vesicles, their lipid-based composition as well as their ability to enhance peptide penetration on vaginal tissue led us to consider this formulation as a better nanosystem than polymeric nanoparticles for the sustained delivery of the HIV-1 fusion inhibitor peptide in vaginal tissues

Design, Characterization, and Biopharmaceutical Behavior of Nanoparticles Loaded with an HIV‑1 Fusion Inhibitor Peptide

New therapeutic alternatives to fight against the spread of HIV-1 are based on peptides designed to inhibit the early steps of HIV-1 fusion in target cells. However, drawbacks, such as bioavailability, short half-life, rapid clearance, and poor ability to cross the physiological barriers, make such peptides unattractive for the pharmaceutical industry. Here we developed, optimized, and characterized polymeric nanoparticles (NPs) coated with glycol chitosan to incorporate and release an HIV-1 fusion inhibitor peptide (E1) inside the vaginal mucosa. The NPs were prepared by a modified double emulsion method, and optimization was carried out by a factorial design. In vitro, ex vivo, and in vivo studies were carried out to evaluate the optimized formulation. The results indicate that the physicochemical features of these NPs enable them to incorporate and release HIV fusion inhibitor peptides to the vaginal mucosa before the fusion step takes place. KEYWORDS: GB virus C, HIV-1, fusion inhibitor peptide of HIV-1, polymeric nanoparticles, factorial design, permeation studie

Cytotoxicity assessment and suspected screening of PLASTIC ADDITIVES in bioplastics of single-use household items

Bioplastics made of renewable sources provide an excellent alternative to fossil-based materials. However, similar or greater quantities of plastic additives than fossil-based plastics are used in the formulations of bioplastics to improve their performance and barrier properties. Nowadays, there is an increasing concern about sources of chemical exposure. However, there is an important knowledge gap regarding complex additive mixtures, particularly in bio-based materials. In this study, we have characterised the presence of plastic additives in single-use materials (collected from retail shops in Spain), which are made of the most common bio-based biodegradable materials, poly(lactic acid) (PLA) and poly(hydroxybutyrate) (PHB), in contrast with a fossil-based plastic material that is extensively made from high-density polyethylene (HDPE). The approach consisted of the pulverization of material in the nano-micro range (100 nm-10 μm), with the materials being extracted using different solvents and ultrasonic-assisted solvent extraction (UASE). 100% of the additives in the material cannot be extracted, but since they were performed in the same condition for all materials can inform about the fingerprint of primary organics and the relative abundances between the different materials. The extracts were analysed by high-performance liquid chromatography coupled with high-resolution mass spectrometry equipped with a heated electrospray ionisation source operated in positive and negative ionisation conditions (HPLC-HESI(+/-)-HRMS), separately, using a suspect screening approach. A total number of 203 additives were tentatively identified (confidence level 2) in the bioplastics items of this study. An average of 123 plastic additives were found in PLA items and 121 in PHB items. Plasticisers were the most abundant additives; the phthalates group was the most commonly found, while 63 plastic additives were confirmed by standards and quantified. In parallel, the cytotoxicity of plastic particles in terms of cell viability and oxidative stress was studied using A549 alveolar basal epithelial cells, and the toxicity of the different extracts was also established using HepG2 adenocarcinoma cells. The main results of this study demonstrate that the plastic particles did not show a significant reduction in cell viability, but oxidative stress was significant, with PLA being the material that showed the highest effect. On the other hand, extracts of plastic particles did not show inhibition of cell viability except for HDPE extract, but the different extracts produced oxidative stress, with PLA showing the highest effect. Although the item showing the highest concentrations of additives was the extract of PLA material while also showing the most elevated oxidative stress, the low migration of toxicants from plastic materials ensures their safe use. However, this also supports the idea that bioplastics can contain many toxic substances in their formulations, some of which are unknown and should be studied in more depth.This work was supported by IMAGE (ref. PID2020-116789RB-C41) from the Spanish Ministry of Science and Innovation, and Sinergia 2021 project within the frame of CEX2018-000794-S IDAEA-projects. Katerina Savva gives thanks her grant from Severo Ochoa (CEX2018-000794-S). IDAEA-CSIC is a Severo Ochoa Centre of Excellence, CEX2018-000794-S funded by MCIN/AEI/10.13039/501100011033.Peer reviewe

Design, Characterization, and Biopharmaceutical Behavior of Nanoparticles Loaded with an HIV‑1 Fusion Inhibitor Peptide

New therapeutic alternatives to fight against the spread of HIV-1 are based on peptides designed to inhibit the early steps of HIV-1 fusion in target cells. However, drawbacks, such as bioavailability, short half-life, rapid clearance, and poor ability to cross the physiological barriers, make such peptides unattractive for the pharmaceutical industry. Here we developed, optimized, and characterized polymeric nanoparticles (NPs) coated with glycol chitosan to incorporate and release an HIV-1 fusion inhibitor peptide (E1) inside the vaginal mucosa. The NPs were prepared by a modified double emulsion method, and optimization was carried out by a factorial design. In vitro, ex vivo, and in vivo studies were carried out to evaluate the optimized formulation. The results indicate that the physicochemical features of these NPs enable them to incorporate and release HIV fusion inhibitor peptides to the vaginal mucosa before the fusion step takes place. KEYWORDS: GB virus C, HIV-1, fusion inhibitor peptide of HIV-1, polymeric nanoparticles, factorial design, permeation studie